<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Dabigatran | Management | Anticoagulation - oral  | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers prescribing and management information for adults receiving dabigatran for use within its licensed indication."/><meta data-react-helmet="true" property="og:description" content="Covers prescribing and management information for adults receiving dabigatran for use within its licensed indication."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/anticoagulation-oral/management/dabigatran/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Dabigatran | Management | Anticoagulation - oral  | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/anticoagulation-oral/management/dabigatran/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Anticoagulation - oral </a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Dabigatran</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/anticoagulation-oral/","name":"Anticoagulation - oral "}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/anticoagulation-oral/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Dabigatran"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Anticoagulation - oral : </span><span>Scenario: Dabigatran</span></h1><p class="page-header__lead"><span>January 2021</span></p></div><p class="visually-hidden">Covers prescribing and management information for adults receiving dabigatran for use within its licensed indication.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Anticoagulation - oral  chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Apixaban"><a aria-current="false" href="../apixaban/index.html"><span class="stacked-nav__content-wrapper">Scenario: Apixaban</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Dabigatran"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Dabigatran</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Edoxaban"><a aria-current="false" href="../edoxaban/index.html"><span class="stacked-nav__content-wrapper">Scenario: Edoxaban</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Rivaroxaban"><a aria-current="false" href="../rivaroxaban/index.html"><span class="stacked-nav__content-wrapper">Scenario: Rivaroxaban</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Warfarin"><a aria-current="false" href="../warfarin/index.html"><span class="stacked-nav__content-wrapper">Scenario: Warfarin</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#recommended-dose-treatment-duration">Recommended dose and treatment duration</a><ol aria-label="Sections within Recommended dose and treatment duration" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-ad1">Basis for recommendation</a></li></ol></li><li><a href="index.html#contraindications-cautions">Contraindications and cautions</a><ol aria-label="Sections within Contraindications and cautions" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-89a">Basis for recommendation</a></li></ol></li><li><a href="index.html#adverse-effects">Adverse effects</a><ol aria-label="Sections within Adverse effects" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-e28">Basis for recommendation</a></li></ol></li><li><a href="index.html#drug-interactions">Drug interactions</a><ol aria-label="Sections within Drug interactions" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-77c">Basis for recommendation</a></li></ol></li><li><a href="index.html#switching-anticoagulants">Switching anticoagulants</a><ol aria-label="Sections within Switching anticoagulants" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-60a">Basis for recommendation</a></li></ol></li><li><a href="index.html#surgery-dental-treatment">Surgery and dental treatment</a><ol aria-label="Sections within Surgery and dental treatment" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#bleeding-risk">Bleeding risk</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-8e7">Basis for recommendation</a></li></ol></li><li><a href="index.html#monitoring">Monitoring</a><ol aria-label="Sections within Monitoring" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-3a0">Basis for recommendation</a></li></ol></li><li><a href="index.html#monitoring-during-the-covid-19-pandemic">Monitoring during the Covid-19 pandemic</a><ol aria-label="Sections within Monitoring during the Covid-19 pandemic" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-232">Basis for recommendation</a></li></ol></li><li><a href="index.html#managing-dosing-errors">Managing dosing errors</a><ol aria-label="Sections within Managing dosing errors" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-47f">Basis for recommendation</a></li></ol></li><li><a href="index.html#advice-to-patients">Advice to patients</a><ol aria-label="Sections within Advice to patients" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-19c">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="dabigatran" class="ChapterBody-module--wrapper--2HCfk "><h2 id="dabigatran" class="visually-hidden">Scenario: Dabigatran</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item fc2dac90-2d08-4722-8272-625527769b30 --><!-- begin field d9084338-9900-4eee-8980-acd900add82c --><p>From age 16 years onwards.</p><!-- end field d9084338-9900-4eee-8980-acd900add82c --><!-- end item fc2dac90-2d08-4722-8272-625527769b30 --></div><section aria-labelledby="recommended-dose-treatment-duration" class="ChapterBody-module--wrapper--2HCfk "><h3 id="recommended-dose-treatment-duration">What is the recommended dose and duration of treatment for dabigatran?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item f56ac90c-15d9-43a0-b314-991904a5c572 --><!-- begin field 820e0ebe-8859-45ec-ada8-8ceb4ac28791 --><ul><li><strong>F</strong><strong>or the prophylaxis of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) and with one or more risk factors, such as previous stroke or transient ischaemic attack, symptomatic heart failure, age 75 years or older, diabetes mellitus, or hypertension:</strong><br><ul><li>The recommended dose is 150 mg twice a day.</li><li>A reduced dose of 110150 mg twice daily is recommended if the person:<ul><li>Is aged 7579 years.</li><li>Has moderate renal impairment (creatinine clearance [CrCl] 3050 mL/minute), based on individual assessment of thromboembolic risk and risk of bleeding.</li><li>Is at increased risk of bleeding.</li></ul></li><li>A reduced dose of 110 mg twice daily is recommended if the person:<ul><li>Is aged 80 years and older.</li><li>Is receiving concurrent treatment with verapamil. See the section on <a class="topic-reference internal-reference" href="index.html#drug-interactions">Drug interactions</a> for more information.</li></ul></li><li>Treatment is usually long term.</li></ul></li><li><strong>For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE, </strong>following initial use of parenteral anticoagulation for at least 5 days:<ul><li>The recommended dose is 150 mg twice daily.</li><li>A reduced dose of 110150 mg twice daily is recommended if the person:<ul><li>Is aged 7579 years.</li><li>Has moderate renal impairment (CrCl 3050 mL/minute), based on individual assessment of thromboembolic risk and risk of bleeding.</li><li>Is at increased risk of bleeding.</li></ul></li><li>A reduced dose of 110 mg twice daily is recommended if the person:<ul><li>Is aged 80 years and older.</li><li>Is receiving concurrent treatment with verapamil. See the section on <a class="topic-reference internal-reference" href="index.html#drug-interactions">Drug interactions</a>for more information.</li></ul></li><li>The duration of treatment is based on an assessment of benefit against the risk for bleeding:<ul><li>Short duration of treatment (at least 3 months) should be based on transient risk factors (for example recent surgery, trauma, immobilization).</li><li>Longer durations of treatment should be based on permanent risk factors or idiopathic DVT or PE.</li></ul></li></ul></li><li><strong>For the prevention of venous thromboembolism (VTE) in people who have undergone knee replacement surgery:</strong><ul><li>The recommended dose is 110 mg to be taken 14 hours after surgery, followed by 220 mg once daily for 10 days.</li><li>A reduced dose of 75 mg taken 14 hours after surgery, followed by 150 mg once daily for 10 days is recommended if the person:<br><ul><li>Is aged 75 years or older.</li><li>Is receiving concurrent treatment with verapamil. See the section on<a class="topic-reference internal-reference" href="index.html#drug-interactions">Drug interactions</a> for more information.</li><li>Has moderate renal impairment (CrCl 3050 mL/minute).</li></ul></li></ul></li><li><strong>For the prevention of VTE in people who have undergone hip replacement surgery:</strong><ul><li>The recommended dose is 110 mg to be taken 14 hours after surgery, followed by 220 mg once daily for 2835 days.</li><li>A reduced dose of 75 mg taken 14 hours after surgery, followed by 150 mg once daily for 2835 days is recommended if the person<br><ul><li>Is aged 75 years or older.</li><li>Is receiving concurrent treatment with verapamil. See the section on<a class="topic-reference internal-reference" href="index.html#drug-interactions">Drug interactions</a>for more information.</li><li>Has moderate renal impairment (CrCl 3050 mL/minute).</li></ul></li></ul></li></ul><!-- end field 820e0ebe-8859-45ec-ada8-8ceb4ac28791 --><!-- end item f56ac90c-15d9-43a0-b314-991904a5c572 --></div><section aria-labelledby="basis-for-recommendation-ad1" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-ad1">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ad18797c-de82-48f4-bd32-a4dfa4459d40 --><!-- begin field 7cc3421d-b479-43ca-8047-4bbb66e15f7b --><p>These recommendations are based on the manufacturer's Summaries of Product Characteristics (SPCs) [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020d</a>] and the British National Formulary (BNF)[<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].</p><ul><li>The manufacturer states that dose reductions are recommended for people taking dabigatran and verapamil. However, no dose adjustment of dabigatran is necessary for concurrent use with amiodarone or quinidine [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020d</a>]. See the section on<a class="topic-reference internal-reference" href="index.html#drug-interactions">Drug interactions</a>for more information.</li></ul><!-- end field 7cc3421d-b479-43ca-8047-4bbb66e15f7b --><!-- end item ad18797c-de82-48f4-bd32-a4dfa4459d40 --></div></section></section><section aria-labelledby="contraindications-cautions" class="ChapterBody-module--wrapper--2HCfk "><h3 id="contraindications-cautions">What are the contraindications and cautions for dabigatran?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 7680e84d-c600-4652-999f-a4c48cd8bdca --><!-- begin field 92be987c-24d3-414e-a1a4-6739f3383328 --><ul><li><strong>Dabigatran is contraindicated in:</strong><ul><li>People with:<ul><li>Severe renal impairment (creatine clearance [CrCl] less than 30 mL/minute).</li><li>Active bleeding.</li><li>A prosthetic heart valve increased risk of thromboembolic and bleeding events.</li><li>Antiphospholipid syndrome  increased risk of recurrent thrombotic events.</li><li>Severe hepatic impairment or liver disease expected to have any impact on life expectancy.</li><li>Elevated liver enzymes (if they are more than twice the upper limit of normal).</li></ul></li><li>People with significant risk of major bleeding, such as:<ul><li>Current or recent gastrointestinal ulcer.</li><li>Oesophageal varices.</li><li>Recent brain or spinal injury.</li><li>Recent brain, spine, or ophthalmic surgery.</li><li>Recent intracranial haemorrhage.</li><li>Malignant neoplasm.</li><li>Vascular aneurysm.</li></ul></li><li>Women who are pregnant or breastfeeding  the safety of dabigatran has not been established in these groups.</li></ul></li><li><strong>Dabigatran should be used with caution in the following groups:</strong><ul><li>Elderly people (aged 75 years and older)  <a class="topic-reference internal-reference" href="index.html#recommended-dose-treatment-duration">dose reduction</a>is indicated.</li><li>People with:<ul><li>Moderate renal impairment (CrCl 3050 mL/minute)  <a class="topic-reference internal-reference" href="index.html#recommended-dose-treatment-duration">dose reduction</a> is indicated (approximately 80% of dabigatran is excreted renally).</li><li>Body weight less than 50 kg  close monitoring for signs of bleeding and anaemia is recommended (low body weight may increase plasma concentrations of dabigatran). No dose adjustment is needed.</li><li>Other risk factors for bleeding, such as gastritis, gastro-oesophageal reflux, oesophagitis, recent biopsy, recent major trauma, or thrombocytopenia  close monitoring for signs of bleeding and anaemia is recommended.</li></ul></li><li>People taking certain drugs, including:<ul><li>Verapamil  <a class="topic-reference internal-reference" href="index.html#recommended-dose-treatment-duration">dose reduction</a>is indicated (verapamil increases plasma concentrations of dabigatran).</li><li>Other drugs that can cause bleeding, such as nonsteroidal anti-inflammatory drugs (NSAIDs)  if concurrent treatment is unavoidable, close monitoring for signs of bleeding and anaemia is recommended. See the section on <a class="topic-reference internal-reference" href="index.html#drug-interactions">Drug interactions</a> for more information, and for information on other drug interactions of dabigatran.</li></ul></li></ul></li></ul><!-- end field 92be987c-24d3-414e-a1a4-6739f3383328 --><!-- end item 7680e84d-c600-4652-999f-a4c48cd8bdca --></div><section aria-labelledby="basis-for-recommendation-89a" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-89a">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 89aa4d49-787a-4628-81b8-005ce3877b2b --><!-- begin field 3eb7dc6c-1cb5-4c09-a287-fbbf6e52ef77 --><p>These recommendations are based on <em>The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Steffel, 2018</a>], the manufacturers Summaries of Product Characteristics (SPCs) [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020d</a>], the British National Formulary (BNF)[<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>], and Drug Safety Updates issued by the Medicines and Healthcare products Regulatory Agency (MHRA): <em>Dabigatran (Pradaxa): contraindicated in patients with prosthetic heart value(s) requiring anti-coagulant treatment, because of the risk of thrombosis and haemorrhage</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2013</a>], <em>Direct-acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2019a</a>], and <em>Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2020a</a>].</p><h5>Prosthetic heart valves</h5><ul><li>The MHRA warns that dabigatran is contraindicated in people with prosthetic heart valve(s) requiring anticoagulant treatment related to their valve surgery, regardless of the length of time that has elapsed since valve replacement took place. This is due toan increased risk of thromboembolic and bleeding events in people taking dabigatran who had a mechanical heart valve replacement compared with people taking warfarin [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2013</a>].</li></ul><h5>Antiphospholipid syndrome</h5><ul><li>A clinical trial has shown an increased risk of recurrent thrombotic events associated with rivaroxaban compared with warfarin in people with antiphospholipid syndrome and a history of thrombosis; there may be a similar risk associated with other DOACs. The MHRA advises that DOACs are not recommended in people with antiphospholipid syndrome, particularly high-risk individuals who test positive for all three antiphospholipid tests  lupus anticoagulant, anticardiolipin antibodies, and anti-beta-2 glycoprotein I antibodies. Continued treatment should be reviewed in these people to determine if appropriate and switching to a vitamin K antagonist (such as warfarin) should be considered [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2019a</a>].</li></ul><h5>Bleeding risk</h5><ul><li>The MHRA reminds healthcare professionals to remain vigilant for signs and symptoms of bleeding complications during treatment with dabigatran after ongoing reports of serious, potentially fatal bleeds associated with the use of DOACs. Healthcare professionals are also advised to use dabigatran with caution in people with increased bleeding risk and to ensure that those with renal impairment are dosed appropriately and their renal function monitored during treatment [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2020a</a>].</li></ul><h5>Renal function</h5><ul><li>Expert opinion in the European Heart Rhythm Association (EHRA) guideline is that approximately 80% of dabigatran is excreted renally. Exposure to dabigatran is substantially increased in people with renal insufficiency, leading to an increased risk of bleeding [<a class="bibliography-reference internal-reference" href="../../references/index.html">Steffel, 2018</a>].</li></ul><!-- end field 3eb7dc6c-1cb5-4c09-a287-fbbf6e52ef77 --><!-- end item 89aa4d49-787a-4628-81b8-005ce3877b2b --></div></section></section><section aria-labelledby="adverse-effects" class="ChapterBody-module--wrapper--2HCfk "><h3 id="adverse-effects">What are the adverse effects of dabigatran?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ffe80579-d159-41bf-8f91-75c8e1d5b9e5 --><!-- begin field 943a7fb8-6cb0-4a53-8a4b-e20c6183ae45 --><ul><li><strong>Bleeding is a common adverse effect of all anticoagulants, including dabigatran,</strong><strong>and it can occur in any part of the body.</strong><ul><li>Advise people taking dabigatran to:<ul><li>Seek immediate medical advice if spontaneous bleeding occurs and does not stop, or recurs. This includes bruising, bleeding gums, nosebleeds, prolonged bleeding from cuts, blood in the urine or stools, haemoptysis, subconjunctival haemorrhage, and vaginal bleeding in a postmenopausal woman.</li><li>Seek medical advice if they get sudden severe back pain (which may indicate spontaneous retroperitoneal bleeding).</li><li>Get advice from a doctor or pharmacist before taking other medications, including over-the-counter medicines (such as nonsteroidal anti-inflammatory drugs) and herbal remedies, due to possible <a class="topic-reference internal-reference" href="index.html#drug-interactions">drug interactions</a> with dabigatran.</li></ul></li><li style="box-sizing: inherit;">Idarucizumab (Praxbind) is a specific reversal agent indicated in adults treated with dabigatran when rapid reversal of its anticoagulant effects is required.</li></ul></li><li><strong>Other adverse effects of dabigatran include:</strong><ul><li>Common  abnormal hepatic function.</li><li>Uncommon  anaemia, diarrhoea, hyperbilirubinaemia, nausea, post procedural/wound complications, and vomiting.</li><li>Rare or very rare  angioedema, dysphagia, gastrointestinal discomfort, gastrointestinal disorders, post procedural drainage, skin reactions, thrombocytopenia, and wound drainage.</li><li>Frequency unknown  agranulocytosis and bronchospasm.</li></ul></li></ul><!-- end field 943a7fb8-6cb0-4a53-8a4b-e20c6183ae45 --><!-- end item ffe80579-d159-41bf-8f91-75c8e1d5b9e5 --></div><section aria-labelledby="basis-for-recommendation-e28" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-e28">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e28d90c2-800c-4d06-981c-26e07570c253 --><!-- begin field 8d73ec6e-1e33-4404-93f1-ea499553d212 --><p>These recommendations are based on theBritish National Formulary (BNF)[<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>] and the Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update <em>Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2020a</a>].</p><h5>Bleeding risk</h5><ul><li>The MHRA reminds healthcare professionals to remain vigilant for signs and symptoms of bleeding complications during treatment with dabigatran after ongoing reports of serious, potentially fatal bleeds associated with the use of DOACs. Healthcare professionals are advised to use dabigatran with caution in people with increased bleeding risk and to ensure that those with renal impairment are dosed appropriately and their renal function monitored during treatment. The person should be counselled on the signs and symptoms of bleeding and encouraged to read the patient information leaflet [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2020a</a>].</li><li>Idarucizumab (Praxbind) is a reversal agent for dabigatran etexilate [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020h</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2020a</a>]. Idarucizumab is a humanized monoclonal antibody fragment that binds specifically to dabigatran and its metabolites, thereby reversing the anticoagulant effects [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].</li><li>The adverse effects listed are largely based on the BNF. The manufacturers Summaries of Product Characteristics (SPCs) list several other possible adverse effects of dabigatran[<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020d</a>].</li></ul><!-- end field 8d73ec6e-1e33-4404-93f1-ea499553d212 --><!-- end item e28d90c2-800c-4d06-981c-26e07570c253 --></div></section></section><section aria-labelledby="drug-interactions" class="ChapterBody-module--wrapper--2HCfk "><h3 id="drug-interactions">What are the key drug interactions for dabigatran?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 73b7a955-a791-479c-8a4a-5f3124a4132b --><!-- begin field e1904481-c9fd-4b98-83ae-333f86eaf6c4 --><ul><li><strong>Key drug interactions with dabigatran include:</strong><ul><li><strong>Nonsteroidal anti-inflammatory drugs (NSAIDs)</strong> dabigatran is predicted to increase the risk of bleeding events when given with NSAIDs (such as ibuprofen).<ul><li>The manufacturer of dabigatran advises to avoid.</li><li>If concurrent use is indicated, monitor closely for signs of bleeding or anaemia.</li></ul></li><li><strong>Other anticoagulants, such as heparin, warfarin, dabigatran, edoxaban, and rivaroxaban </strong> there is an increased risk of bleeding if other anticoagulants are given with dabigatran.<ul><li>Avoid concurrent use except when switching to or from warfarin treatment. See the section on <a class="topic-reference internal-reference" href="index.html#switching-anticoagulants">Switching anticoagulants</a> for more information.</li></ul></li><li><strong>Antiplatelets, such as aspirin, clopidogrel, and ticagrelor </strong> dabigatran is predicted to increase the risk of bleeding events when given with antiplatelet drugs.<ul><li>The manufacturer of dabigatran advises to avoid.</li><li>If concurrent use is indicated, monitor closely for signs of bleeding or anaemia.</li></ul></li><li><strong>Strong inhibitors of P-glycoprotein (P-gp), such as ciclosporin, dronedarone, itraconazole, and ketoconazole </strong> plasma concentration of dabigatran is increased by these drugs (dabigatran is a substrate for P-gp).<ul><li>The manufacturer of dabigatran advises to avoid concurrent use.</li></ul></li><li><strong>Mild to moderate P-gp inhibitors, such as amiodarone, verapamil, and quinidine</strong>  plasma concentration of dabigatran is increased by these drugs.<br><ul><li>With verapamil, reduce the <a class="topic-reference internal-reference" href="index.html#recommended-dose-treatment-duration">dose of dabigatran</a> to 110 mg twice daily, and monitor for signs of bleeding.</li><li>With amiodarone and quinidine, the manufacturer of dabigatran advises that no dose adjustment is necessary but the person should be monitored closely for signs of bleeding or anaemia.</li></ul></li><li><strong>Strong inducers of P-gp, such as carbamazepine, phenytoin, rifampicin, and St John's Wort </strong> plasma concentration of dabigatran is reduced by these drugs.<ul><li>The manufacturer of dabigatran advises to avoid concurrent use with these drugs.</li></ul></li><li><strong>Selective serotonin reuptake inhibitors (such as citalopram), serotonin norepinephrine re-uptake inhibitors (duloxetine), and venlafaxine </strong> there is a possible increased risk of bleeding when dabigatran is given with these antidepressants.<ul><li>The manufacturer of dabigatran advises to avoid concurrent use.</li><li>If concurrent use is indicated, monitor closely for signs of bleeding or anaemia.</li></ul></li></ul></li><li>See the <a href="http://www.medicines.org.uk/emc" data-hyperlink-id="bf6bda62-14be-48b6-a3bd-a98d000d45b6">electronic Medicines Compendium</a>(eMC) or the<a href="https://bnf.nice.org.uk/" data-hyperlink-id="f811dbb2-4c9a-4436-be05-a98d000d462f">British National Formulary</a> (BNF) for other possible drug interactions with dabigatran.</li></ul><!-- end field e1904481-c9fd-4b98-83ae-333f86eaf6c4 --><!-- end item 73b7a955-a791-479c-8a4a-5f3124a4132b --></div><section aria-labelledby="basis-for-recommendation-77c" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-77c">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 77c8b6c4-b94d-4695-8e12-e2aae470f4d2 --><!-- begin field 59538b25-a09b-4d10-a973-c8757eb04ccd --><p>These recommendations are based on the manufacturer's Summaries of Product Characteristics (SPCs)[<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020d</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020b</a>]and the British National Formulary (BNF)[<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].</p><!-- end field 59538b25-a09b-4d10-a973-c8757eb04ccd --><!-- end item 77c8b6c4-b94d-4695-8e12-e2aae470f4d2 --></div></section></section><section aria-labelledby="switching-anticoagulants" class="ChapterBody-module--wrapper--2HCfk "><h3 id="switching-anticoagulants">How should I switch a person to or from another anticoagulant?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 711fc5a6-fa05-497e-9199-18c587e57e6f --><!-- begin field 8750de51-4666-4a74-9728-e5706078bbac --><ul><li><strong>Switching from warfarin to dabigatran:</strong><ul><li>Stop warfarin, and measure the international normalized ratio (INR):<ul><li>If the INR is less than 2, start dabigatran.</li><li>If the INR is between 2 and 2.5, start dabigatran the next day.</li><li>If the INR is greater than 2.5, wait until the person's INR has dropped to less than 2 before starting dabigatran.</li></ul></li><li>The time taken for the person's INR to reach less than 2 will vary from person to person and will depend on what the person's initial INR level was.</li></ul></li><li><strong>Switching from dabigatran to warfarin:</strong><ul><li>Start warfarin, but <em>do not</em>stop dabigatran.<ul><li>See the section on<a class="topic-reference internal-reference" href="../warfarin/index.html#starting-warfarin-treatment">Starting warfarin treatment</a> for information on how to initiate warfarin treatment.</li></ul></li><li>After at least 2 days of concurrent treatment with warfarin and dabigatran, measure the INR prior to the next scheduled dose of dabigatran.<br><ul><li>If the INR is in the target range, stop dabigatran and continue with warfarin.</li><li>If the INR is not in the target range, continue warfarin and dabigatran concurrently until the person's INR is in the target range, then stop dabigatran. Warfarin has a slow onset of action and it may take 510 days before the INR is within range.</li></ul></li><li>After treatment with dabigatran has stopped:<ul><li>Measure the INR after 24 hours to ensure adequate anticoagulation.</li><li>Monitor the person's INR closely (for example once a week) in the first month of warfarin treatment until the person has three consecutive stable INR values (for example between 23).</li></ul></li></ul></li><li><strong>Switching from dabigatran</strong><strong>to another direct-acting oral anticoagulant (DOAC):</strong><ul><li>Stop dabigatran, and start the new DOAC (apixaban, edoxaban, or rivaroxaban) when the next dose of dabigatran is due.<ul><li>In situations where higher than therapeutic plasma concentrations are expected, such as in people with impaired renal function, a longer interval in between DOACs is recommended.</li></ul></li></ul></li><li><strong>Switching from another DOAC to dabigatran:</strong><ul><li>Stop the initial DOAC (apixaban, edoxaban, or rivaroxaban), and start dabigatran when the next dose of the initial DOAC (apixaban, edoxaban, or rivaroxaban) is due.<ul><li>In situations where higher than therapeutic plasma concentrations are expected, such as in people with impaired renal function, a longer interval in between DOACs is recommended.</li></ul></li></ul></li></ul><!-- end field 8750de51-4666-4a74-9728-e5706078bbac --><!-- end item 711fc5a6-fa05-497e-9199-18c587e57e6f --></div><section aria-labelledby="basis-for-recommendation-60a" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-60a">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 60a21798-16b7-4646-9150-76bad7f94a19 --><!-- begin field 06585828-f623-4607-a125-33b1bdab6236 --><p>These recommendations are based on the manufacturer's Summaries of Product Characteristics (SPCs) [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020d</a>]and<em>The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Steffel, 2018</a>].</p><!-- end field 06585828-f623-4607-a125-33b1bdab6236 --><!-- end item 60a21798-16b7-4646-9150-76bad7f94a19 --></div></section></section><section aria-labelledby="surgery-dental-treatment" class="ChapterBody-module--wrapper--2HCfk "><h3 id="surgery-dental-treatment">Should dabigatran be stopped if surgery or dental treatment is required?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item d69dfe2f-3a9b-439e-989c-53d1a9963c28 --><!-- begin field 02c0be2f-c1e9-498a-bd6e-d3abc4947429 --><ul><li><strong>If the person needs to have surgery or any other invasive procedure, they may need to temporarily stop taking dabigatran. </strong>The decision to stop dabigatran and when to stop it will depend on the person's risk of having a thromboembolic event and the bleeding risk associated with the procedure.</li><li><strong>For most minor surgical procedures and those associated with a</strong><strong><a class="topic-reference internal-reference" href="index.html#bleeding-risk">minor bleeding risk</a>,</strong> it is recommended not to interrupt oral anticoagulation.<ul><li>In general, these procedures can be performed 1224 hours after the last dose of dabigatran is taken.</li><li>It may be practical to have the intervention scheduled 1824 hours after the last dose of dabigatran is taken, then restart dabigatran 6 hours later. This means that one dose of dabigatran may be missed.</li></ul></li><li><strong>For procedures with a<a class="topic-reference internal-reference" href="index.html#bleeding-risk">low bleeding risk</a>,</strong> dabigatran should be stopped at least 24 hours before the procedure.<ul><li>If creatinine clearance (CrCl) is 5079 mL/minute, dabigatran should be stopped at least 36 hours before the procedure.</li><li>If CrCl is 3049 mL/minute, dabigatran should be stopped at least 48 hours before the procedure.</li></ul></li><li><strong>For procedures witha<a class="topic-reference internal-reference" href="index.html#bleeding-risk">high bleeding risk</a>,</strong> dabigatran should be stopped at least 48 hours before the procedure.<ul><li>If CrCl is 5079 mL/minute, dabigatran should be stopped at least 72 hours before the procedure.</li><li>If CrCl is 3049 mL/minute, dabigatran should be stopped at least 96 hours before the procedure.</li></ul></li></ul><!-- end field 02c0be2f-c1e9-498a-bd6e-d3abc4947429 --><!-- end item d69dfe2f-3a9b-439e-989c-53d1a9963c28 --></div><section aria-labelledby="bleeding-risk" class="ChapterBody-module--wrapper--2HCfk "><h4 id="bleeding-risk">Bleeding risk</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ace08dfc-0add-4397-a628-5aefa3bafd19 --><!-- begin field 987b37f0-dbc6-4fe9-b9b3-395d44cc13aa --><ul><ul><li><strong>Treatments with minor bleeding risk include:</strong><ul><li>Dental interventions, such as extraction of 1 to 3 teeth, periodontal surgery, incision of abscess, and implant positioning.</li><li>Cataract or glaucoma interventions.</li><li>Endoscopy without surgery.</li><li>Minor surgery, such as abscess incision and small dermatologic excisions.</li></ul></li><li><strong>Treatments with low bleeding risk include:</strong><ul><li>Endoscopy with biopsy.</li><li>Prostate or bladder biopsy.</li><li>Electrophysiological study or radiofrequency catheter ablation for supraventricular tachycardia, including left-sided ablation via single trans-septal puncture.</li><li>Angiography.</li><li>Pacemaker or implantable cardioverter defibrillator (ICD) implantation (unless complex anatomical setting, for example congenital heart disease).</li></ul></li><li><strong>Treatments with high bleeding risk include:</strong><ul><li>Complex endoscopy, such as polypectomy and endoscopic retrograde cholangiopancreatography (ERCP) with sphincterotomy.</li><li>Spinal or epidural anaesthesia.</li><li>Lumbar diagnostic puncture.</li><li>Thoracic surgery.</li><li>Abdominal surgery.</li><li>Major orthopaedic surgery.</li><li>Liver biopsy.</li><li>Transurethral prostate resection.</li><li>Kidney biopsy.</li><li>Extracorporeal shockwave lithotripsy (ESWL).</li></ul></li><li><strong>Treatments with high bleeding risk<em>and</em>increased thromboembolic risk include:</strong><ul><li>Complex left-sided ablation (pulmonary vein isolation and some VT ablations).</li></ul></li></ul></ul><p>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Steffel, 2018</a>]</p><!-- end field 987b37f0-dbc6-4fe9-b9b3-395d44cc13aa --><!-- end item ace08dfc-0add-4397-a628-5aefa3bafd19 --></div></section><section aria-labelledby="basis-for-recommendation-8e7" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-8e7">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 8e7ede4e-51ee-4ffb-b927-8e0290cfec2f --><!-- begin field 2c375673-d36b-49b6-bb4c-46609999e653 --><p>These recommendations are largely based on<em>The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Steffel, 2018</a>].</p><h5>Minor bleeding risk</h5><ul><li>The European Heart Rhythm Association (EHRA) recommends not to interrupt oral anticoagulation for most minor surgical procedures and those procedures where bleeding is easily controllable.</li></ul><h5>Low bleeding risk</h5><ul><li>For invasive procedures with a low bleeding risk (that is, low frequency of bleeding and/or minor impact of bleeding), the EHRA recommends taking the last dose of dabigatran 24 hours before the procedure in people with normal renal function. For people on dabigatran with creatinine clearance (CrCl) less than 80 mL/minute, a graded interruption should be considered:<ul><li>The EHRA recommends an interruption of at least 36 hours if CrCl is 5079 mL/minute and at least 48 hours if CrCl is 3049 mL/minute.</li><li>The manufacturer of dabigatran recommends an interruption of 2448 hours if CrCl is 5079 mL/minute, and 4872 hours (more than 48 hours) if CrCl is 3049 mL/minute [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020d</a>].</li></ul></li></ul><h5>High bleeding risk</h5><ul><li>For invasive procedures that carry a high risk for major bleeding (that is, with a high frequency of bleeding and/or important clinical impact), the EHRA recommends taking the last direct oral anticoagulant (DOAC) dose 48 hours or longer before surgery. The decision to halt treatment for longer should take into account the persons thromboembolic risk compared with the bleeding risk, as well as concurrent treatment with antiarrhythmic drugs. In people with impaired renal function, longer interruption of the anticoagulant intake is required, especially for dabigatran.</li></ul><!-- end field 2c375673-d36b-49b6-bb4c-46609999e653 --><!-- end item 8e7ede4e-51ee-4ffb-b927-8e0290cfec2f --></div></section></section><section aria-labelledby="monitoring" class="ChapterBody-module--wrapper--2HCfk "><h3 id="monitoring">How should I monitor a person taking dabigatran?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item b5e3c847-7ca2-45f0-92ec-23c290aca60c --><!-- begin field 49ada5f6-acb5-484f-bf09-d06250dfa776 --><p><strong>There is no need to monitor the international normalized ratio (INR) in people taking dabigatran; however,</strong><strong>regular follow up and monitoring is recommended.</strong></p><ul><ul><li><strong>At the start of treatment,</strong>baseline clotting screen, renal and liver function tests, and a full blood count should be performed.</li><li><strong>Once treatment has started,</strong>review the person on a regular basis, preferably after 1 month initially and at least every 3 months thereafter. Follow-up intervals may be longer (up to every 6 months) or shorter (for example every month) depending on patient factors, such as renal function, age, and comorbidities.</li><li><strong>During a review:</strong><ul><li>Assess adherence to treatment.</li><li>Look for signs of bleeding or anaemia.</li><li>Ask about other <a class="topic-reference internal-reference" href="index.html#adverse-effects">adverse effects</a>of dabigatran.</li><li>Assess for the presence of thromboembolic events, such as symptoms of stroke, or breathlessness (which may suggest a pulmonary embolism). See the CKS topics on <a class="topic-reference external-reference" href="../../../stroke-tia/index.html">Stroke and TIA</a>and<a class="topic-reference external-reference" href="../../../pulmonary-embolism/index.html">Pulmonary embolism</a>for more information.</li><li>Ask about the use of other medications, including over-the-counter (OTC) products, to identify possible <a class="topic-reference internal-reference" href="index.html#drug-interactions">drug interactions</a> with dabigatran.</li><li>Assess and minimize modifiable risk factors for bleeding, such as uncontrolled hypertension, medication predisposing for bleeding (such as aspirin), and excessive alcohol intake.</li><li>Give appropriate information and advice on dabigatran treatment. See the section on <a class="topic-reference internal-reference" href="index.html#advice-to-patients">Advice for patients</a> for more information.</li></ul></li><li><strong>Repeat the<strong>full blood count and the</strong>renal and liver function tests yearly for most people.</strong><ul><li>If the person is frail or older than 75 years, repeat the blood tests every 6 months.</li><li>If the person has a creatinine clearance (CrCl) less than 60 mL/minute, the frequency of monitoring (in months) can be guided by the CrCl divided by 10. For example, every 3 months if CrCl is 30 mL/minute.</li><li>If the person has an intercurrent illness that may impact renal or hepatic function, repeat renal and liver function tests as needed.</li></ul></li><li><strong>Manage any problems identified during a review or from blood test results.</strong><ul><li>If renal function has declined, review treatment dabigatran may need to be stopped or a <a class="topic-reference internal-reference" href="index.html#recommended-dose-treatment-duration">lower dose</a> may be required.</li><li>If there is an unexplained fall in haemoglobin and/or haematocrit, occult bleeding may be present (dabigatran can cause bleeding from any site)  stop treatment with dabigatran and seek specialist advice.</li></ul></li><li><strong>See the section on<a class="topic-reference internal-reference" href="index.html#monitoring-during-the-covid-19-pandemic">Monitoring during Covid-19 pandemic</a>for more monitoring advice.</strong></li></ul></ul><!-- end field 49ada5f6-acb5-484f-bf09-d06250dfa776 --><!-- end item b5e3c847-7ca2-45f0-92ec-23c290aca60c --></div><section aria-labelledby="basis-for-recommendation-3a0" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-3a0">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 3a0886dc-a475-48af-be70-f2d5b074016f --><!-- begin field dcb9e26b-3735-40b1-ad7e-f894a685e6a4 --><p>These recommendations are based on<em>The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Steffel, 2018</a>],the manufacturer's Summaries of Product Characteristics (SPCs)[<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020d</a>],the Medicines and Healthcare products Regulatory Agency (MHRA)Drug Safety Update<em>Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2020a</a>],and the British National Formulary (BNF)[<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].</p><h5>Regular monitoring of dabigatran treatment</h5><ul><li>No routine anticoagulant monitoring is required during treatment with dabigatran  international normalized ratio (INR) tests give misleading results[<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>]. However, regular follow up and monitoring is recommended.</li><li>The European Heart Rhythm Association (EHRA) states that treatment with DOACs requires vigilance due to potentially severe complications, especially as the target patient population tends to be frail and of older age. According to the EHRA [<a class="bibliography-reference internal-reference" href="../../references/index.html">Steffel, 2018</a>]:<br><ul><li>DOACs have an improved efficacy/safety ratio, a predictable anticoagulant effect without need for routine coagulation monitoring, and fewer drug interactions than warfarin. However, treatment should be reviewed on a regular basis, preferably after 1 month initially and at least every 3 months thereafter. As clinical experience with these medications grows, follow-up intervals may become longer, based on individual (patient-specific) or local (centre-specific) factors. (The EHRA guideline gives a recommended follow-up interval of 16 months.)</li><li>The absence of a need for routine plasma level monitoring means that people taking DOACs are likely to be less frequently seen for follow-up appointments than people on warfarin treatment. Regular follow-up assessment is useful, especially for people with comorbidities (such as renal failure, older age, multiple comorbidities, or frailty).</li></ul></li></ul><h5>Renal function tests</h5><ul><li>Regular renal function tests are required as approximately 80% of dabigatran is excreted renally. Exposure to dabigatran is substantially increased in people with renal insufficiency, leading to an increased risk of bleeding. The EHRA advises that renal function should be monitored every 6 months if the person is frail or aged over 75 years, or more frequently if creatinine clearance (CrCl) is less than 60 mL/minute [<a class="bibliography-reference internal-reference" href="../../references/index.html">Steffel, 2018</a>].</li></ul><h5>Bleeding risk</h5><ul><li>The MHRA reminds healthcare professionals to remain vigilant for signs and symptoms of bleeding complications during treatment with dabigatran after ongoing reports of serious, potentially fatal bleeds associated with the use of DOACs. Healthcare professionals are advised to use dabigatran with caution in people with increased bleeding risk and to ensure that those with renal impairment are dosed appropriately and their renal function monitored during treatment. People should be counselled on the signs and symptoms of bleeding and encouraged to read the patient information leaflet [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2020a</a>].</li><li>The SPCs and the BNF state that, as with other anticoagulants, people taking dabigatran should be carefully monitored for signs of bleeding and treatment should be discontinued if bleeding occurs [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020c</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].</li></ul><!-- end field dcb9e26b-3735-40b1-ad7e-f894a685e6a4 --><!-- end item 3a0886dc-a475-48af-be70-f2d5b074016f --></div></section></section><section aria-labelledby="monitoring-during-the-covid-19-pandemic" class="ChapterBody-module--wrapper--2HCfk "><h3 id="monitoring-during-the-covid-19-pandemic">How should I monitor a person taking dabigatran during the COVID-19 pandemic?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e04e7e1b-9278-4452-9379-f7de4e192402 --><!-- begin field ab78de09-2223-47f1-8769-acb401762b5d --><ul><li><strong>When monitoring a person taking dabigatran during the COVID-19 pandemic, remember that:</strong><br><ul><li>Direct-acting oral anticoagulants (DOACs), such as dabigatran, may<a class="topic-reference internal-reference" href="index.html#drug-interactions">interact</a> with other medicines, including antibacterials and antivirals. Follow the advice in the manufacturer's Summary of Product Characteristics (SPC), available on the <a href="http://www.medicines.org.uk/emc" data-hyperlink-id="bf6bda62-14be-48b6-a3bd-a98d000d45b6">electronic Medicines Compendium</a> (eMC) website, to minimize the risk of potential interactions.</li><li>If switching from warfarin to dabigatran, stop warfarin before starting dabigatran, to reduce the risk of over-anticoagulation and bleeding. See the section on<a class="topic-reference internal-reference" href="index.html#switching-anticoagulants">Switching anticoagulants</a>for more information.</li></ul></li></ul><!-- end field ab78de09-2223-47f1-8769-acb401762b5d --><!-- end item e04e7e1b-9278-4452-9379-f7de4e192402 --></div><section aria-labelledby="basis-for-recommendation-232" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-232">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 232b8e0e-4274-487c-9ee0-dcce3ce3e9bc --><!-- begin field 1460bbae-9cc6-4db7-af52-acb401762b5d --><p>This recommendation is based on theMedicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update<em>Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2020b</a>].</p><!-- end field 1460bbae-9cc6-4db7-af52-acb401762b5d --><!-- end item 232b8e0e-4274-487c-9ee0-dcce3ce3e9bc --></div></section></section><section aria-labelledby="managing-dosing-errors" class="ChapterBody-module--wrapper--2HCfk "><h3 id="managing-dosing-errors">How should I manage dosing errors in a person taking dabigatran?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item b7bc2dfb-53e2-4cf1-a82f-4bb5b38b22ea --><!-- begin field a7302b15-00bf-49f3-9e9c-56f88a75e434 --><ul><li><strong>If the person has missed a dose of dabigatran,</strong>the forgotten dose may be taken until half of the dosing interval has passed.<ul><li>For a twice-daily dosing regimen of dabigatran (every 12 hours), the forgotten dose can be taken up until 6 hours after the scheduled intake. After this time point, the dose should be skipped and the next scheduled dose should be taken.<ul><li style="box-sizing: inherit;">The 6-hour interval may be extended in people with a high stroke risk and low bleeding risk.</li></ul></li><li>For once-daily dosing regimen of dabigatran (every 24 hours), the forgotten dose can be taken up until 12 hours after the scheduled intake. After this time point, the dose should be skipped and the next scheduled dose should be taken.<ul><li>The 12-hour interval may be extended in people with a high stroke risk.</li></ul></li></ul></li><li><strong>If the person has taken a double dose of dabigatran:</strong><ul><li>For a twice-daily dosing regimen of dabigatran, they should omit the next planned dose (that is, after 12 hours) and resume treatment as normal 24 hours after the double dose intake.</li><li>For once-daily dosing regimen of dabigatran, they should take the next dose as normal the following day.</li></ul></li><li><strong>If the person is uncertain whether they have taken their dose:</strong><ul><li>For a twice-daily dosing regimen of dabigatran, it is generally advisable to not take another dose, but to continue with the next scheduled dose (that is, after 12 hours).</li><li>For once-daily dosing regimen of dabigatran, management will depend on the person's thrombotic risk:<ul><li>If thrombotic risk is high (CHA2DS2-VASc score greater than 3), it may generally be advisable to take another dose and then continue the planned dose regimen.</li><li>If thrombotic risk is low (CHA2DS2-VASc score less than 2), it is recommended that they wait until the time of their next scheduled dose.</li></ul></li></ul></li></ul><!-- end field a7302b15-00bf-49f3-9e9c-56f88a75e434 --><!-- end item b7bc2dfb-53e2-4cf1-a82f-4bb5b38b22ea --></div><section aria-labelledby="basis-for-recommendation-47f" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-47f">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 47f8836b-3c06-413c-9649-d25ae168ae1c --><!-- begin field 552600fd-f687-4c3b-9eac-fe9e45afd18e --><p>These recommendations are based on <em>The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Steffel, 2018</a>].</p><!-- end field 552600fd-f687-4c3b-9eac-fe9e45afd18e --><!-- end item 47f8836b-3c06-413c-9649-d25ae168ae1c --></div></section></section><section aria-labelledby="advice-to-patients" class="ChapterBody-module--wrapper--2HCfk "><h3 id="advice-to-patients">What advice should I give a person who is taking dabigatran?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 87cfecbd-abb6-438a-b68d-0332eda454a4 --><!-- begin field 3f935450-4ee0-4afd-aac4-4d0269a7e9c9 --><ul><li><strong>Advise the person taking dabigatran:</strong><ul><li>That although (unlike warfarin) there is no need to have regular blood tests to monitor the international normalized ratio (INR), they will still require regular<a class="topic-reference internal-reference" href="index.html#monitoring">monitoring</a>, blood tests, and review of their treatment.</li><li>On the importance of a regular dosing schedule.<ul><li>The anticoagulant effect of dabigatran reduces 1224 hours after the last dose is taken; therefore, it is important to take dabigatran as directed, in order to reduce the risk of a thromboembolic event.</li><li>They should not miss doses (or take additional doses) without advice from a healthcare professional.</li></ul></li><li>That they should seek immediate medical advice:<ul><li>If spontaneous bleeding occurs and does not stop or recurs. This includes bruising, bleeding gums, nosebleeds, prolonged bleeding from cuts, blood in the urine or stools, haemoptysis, subconjunctival haemorrhage, and vaginal bleeding in a postmenopausal woman.</li><li>If they get sudden severe back pain (which may indicate spontaneous retroperitoneal bleeding).</li><li>If they experience difficulty breathing, increased breathing rate, or chest pain (which could be symptoms of pulmonary embolism).</li></ul></li><li>That they should also seek medical advice:<ul><li>If there has been a <a class="topic-reference internal-reference" href="index.html#managing-dosing-errors">dosing error</a>, for example a missed dose or if a double dose has been taken.</li><li>Before taking other medications, including over-the-counter drugs (such as nonsteroidal anti-inflammatory drugs) and herbal remedies, due to possible <a class="topic-reference internal-reference" href="index.html#drug-interactions">drug interactions</a> with dabigatran.</li><li>If they experience other <a class="topic-reference internal-reference" href="index.html#adverse-effects">adverse effects</a>of dabigatran.</li></ul></li><li>That they may have to stop dabigatran treatment temporarily for certain<a class="topic-reference internal-reference" href="index.html#surgery-dental-treatment">surgical and dental treatments</a>.</li><li>To read the manufacturer's<a href="https://www.medicines.org.uk/emc/product/4703/pil" data-hyperlink-id="e7074f8e-b101-46d1-a5e2-acb300c26292">patient information leaflet</a>, if they have not already.</li><li>To carrya Pradaxa Patient Alert Card at all times. These are contained in each UK tablet pack and can also be printed off from the manufacturer's website (<a href="https://www.pradaxa.co.uk/patient/patient-alert-card" data-hyperlink-id="5ae163a4-3b1b-499e-9e7e-acae013dd9ec">www.pradaxa.co.uk</a>).</li></ul></li></ul><!-- end field 3f935450-4ee0-4afd-aac4-4d0269a7e9c9 --><!-- end item 87cfecbd-abb6-438a-b68d-0332eda454a4 --></div><section aria-labelledby="basis-for-recommendation-19c" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-19c">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 19ccc020-4c4b-44da-91b6-4596011ee485 --><!-- begin field 3987ed23-1c68-4090-afba-b7e14290c7c3 --><p>These recommendations are based on the manufacturer's Summaries of Product Characteristics (SPCs) [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020d</a>] and<em>The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Steffel, 2018</a>].</p><!-- end field 3987ed23-1c68-4090-afba-b7e14290c7c3 --><!-- end item 19ccc020-4c4b-44da-91b6-4596011ee485 --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI"><!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/anticoagulation-oral/management/dabigatran/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>